Aurinia Pharmaceuticals 2026 Forecast | Price, Valuation & Growth

Aurinia Pharmaceutic...

NasdaqGM:AUPH

$ 14,87

$-0,36 (-2,36%)

14,87 $

$-0,36 (-2,36%)

End-of-day quote: 01/15/2026

Aurinia Pharmaceuticals Stock Value

Analysts currently rate NasdaqGM:AUPH as Outperform.

Outperform

Aurinia Pharmaceuticals Company Info

EPS Growth 5Y

15,38%

Market Cap

$1,96 B

Long-Term Debt

$0,01 B

Short Interest

12,90%

Annual earnings

02/26/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

1993

Industry

Health Care

Country

Canada

ISIN Number

CA05156V1022

Website

http://www.auriniapharma.com

Analyst Price Target

$16,50

10.96%

Last Update: 01/16/2026

Analysts: 6

Highest Price Target $21,00

Average Price Target $16,50

Lowest Price Target $13,00

In the last five quarters, Aurinia Pharmaceuticals’s Price Target has risen from $5,98 to $9,83 - a 64,38% increase. Six analysts predict that Aurinia Pharmaceuticals’s share price will increase in the coming year, reaching $16,50. This would represent an increase of 10,96%.

Top growth stocks in the health care sector (5Y.)

What does Aurinia Pharmaceuticals do?

Aurinia Pharmaceuticals Inc. (Aurinia), a biopharmaceutical company, focuses on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (‘LN’). Aurinia is also developing AUR200, a dual inhibitor of B cell activating factor (‘BAFF’) and a proliferation inducing ligand (‘APRIL’) for the potential...

Aurinia Pharmaceuticals Inc. (Aurinia), a biopharmaceutical company, focuses on delivering therapies to people living with autoimmune diseases with high unmet medical needs.

In January 2021, the company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (‘LN’). Aurinia is also developing AUR200, a dual inhibitor of B cell activating factor (‘BAFF’) and a proliferation inducing ligand (‘APRIL’) for the potential treatment of autoimmune diseases.

Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the U.S., and the company sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (‘Otsuka’), for the European and Japanese markets.

In December 2020, the company entered into a collaboration and licensing agreement with Otsuka to develop and commercialize oral voclosporin in Japan, the European Union (the ‘E.U.’), the U.K., Switzerland, Russia, Norway, Belarus, Iceland, Liechtenstein, and Ukraine (collectively, the ‘Otsuka Territories’).

In August 2022, the company entered into a commercial supply agreement with Otsuka to supply LUPKYNIS inventory to Otsuka and provide manufacturing and other services, including sharing the capacity of a dedicated manufacturing facility at Lonza Ltd. (‘Lonza’), the company’s contract manufacturing partner for voclosporin.

Otsuka has obtained regulatory approval of LUPKYNIS in Japan, the E.U., the U.K., and Switzerland.

Product Portfolio

LUPKYNIS (voclosporin)

In January 2021, the company introduced LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (‘LN’). The company markets LUPKYNIS in the U.S. directly through its own commercial organization. In Japan, the European Union (the ‘E.U.’), the United Kingdom (the ‘U.K.’), and Switzerland, LUPKYNIS is marketed by Aurinia’s collaboration partner, Otsuka Pharmaceutical Co., Ltd. (‘Otsuka’).

LUPKYNIS is a calcineurin-inhibitor immunosuppressant indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active LN. LUPKYNIS targets LN with a dual mechanism of action: it promotes podocyte stability, reducing proteinuria; and acts as an immunosuppressant through inhibition of T-cell activation and cytokine production.

Clinical Study Overview of LUPKYNIS

FDA approval of LUPKYNIS was based on the company’s pivotal Phase 3 AURORA 1 study (‘AURORA 1’), which demonstrated the ability of LUPKYNIS treatment to significantly improve outcomes for patients when added to the then-typical standard of care, MMF and corticosteroids. AURORA 1 was a randomized, double-blind, placebo-controlled, Phase 3 study in 357 adults with class III, IV, or V (alone or in combination with class III or IV) LN. In this study, patients receiving LUPKYNIS with MMF plus corticosteroids compared to patients receiving MMF plus corticosteroids alone experienced a significantly higher rate of complete renal response (‘CRR’) at both Week 52 (primary endpoint) and Week 24 (secondary endpoint).

LUPKYNIS in combination with MMF and corticosteroids reduced proteinuria twice as fast as MMF and corticosteroids alone.

In the pivotal Phase 3 study (AURORA 1) and Phase 2 study (AURA-LV), adverse reactions occurring in =3% of patients treated with LUPKYNIS and =2% higher than placebo.

In AURORA 2, a double-blind, placebo-controlled extension study of adults with active LN who completed AURORA 1, LUPKYNIS demonstrated safety comparable to that seen in AURORA 1, with no unexpected safety signals observed through 3 years (LUPKYNIS Prescribing Information and Saxena et al., Arthritis Rheumatol 2024;76(1):59-67). The AURORA Clinical Program is the only clinical program to include 3 years of LN treatment and follow-up.

2024 American College of Rheumatology (‘ACR’) Lupus Nephritis Treatment Guidelines

In part due to the clinical study results with LUPKYNIS, ACR now recommends triple immunosuppressive therapy, including treatment with a calcineurin inhibitor (the class of drugs that includes LUPKYNIS), as first-line therapy for patients with LN, with the goal of treatment being the preservation of kidney function (2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis: Guideline Summary 2024). The ACR-recommended goal of therapy is to reach proteinuria =0.5 mg/mg by 6-12 months. LUPKYNIS’s rapid effect on reducing proteinuria facilitates achieving this treatment goal.

AUR200

AUR200 is a dual inhibitor of B cell activating factor (‘BAFF’) and a proliferation inducing ligand (‘APRIL’) for the potential treatment of autoimmune diseases. AUR200 contains a B cell maturation antigen (‘BCMA’)-engineered extracellular binding domain optimized for superior affinity to BAFF and APRIL (others use transmembrane activator and CAML interactor (‘TACI’)-engineered extracellular binding domain). BCMA has a stronger natural affinity for APRIL than TACI (Mathur, J Clin Med 2023;12:1-18). AUR200 contains an immunoglobulin (‘Ig’) G4 fragment crystallizable region (‘Fc’) domain with no appreciable effector function (others use IgG1 Fc domain). IgG4 is considered the least inflammatory across the IgG subclasses, in part because it poorly activates the complement system (Oskam et al., Front Immun 2023;14:1-11).

BAFF and APRIL are important cytokines that regulate B cell survival and differentiation (Mathur et al., J Clin Med 2023;12:1-18). BAFF and APRIL receptor targets are expressed on B cells at different stages of B cell development (Mathur et al., J Clin Med 2023;12:1-18). Targeting both BAFF and APRIL depletes a broader set of B cells than targeting a single cytokine. By inhibiting BAFF and APRIL, drugs like AUR200 may prevent the activation of autoreactive B cells and reduce their numbers and associated antibodies in the body, thereby treating autoimmune diseases.

Based on preclinical in vitro testing, AUR200 has high binding affinity for both BAFF and APRIL as compared to competitor dual BAFF/APRIL inhibitors, atacicept and telitacicept.

Based on preclinical in vitro testing, AUR200 potently inhibits both BAFF- and APRIL-mediated B cell proliferation as compared to competitor dual BAFF/APRIL inhibitors, atacicept and telitacicept.

In preclinical testing in non-human primates, subcutaneous dosing of AUR200 resulted in significant and sustained reductions in the B cell antibodies immunoglobulin A (‘IgA’) and immunoglobulin M (‘IgM’). AUR200 was well-tolerated, with no adverse findings at any of the doses tested.

A single ascending dose (‘SAD’) study to assess the safety, tolerability, and pharmacodynamics of AUR200 in healthy volunteers was initiated in September 2024 and is ongoing. Initial results from this study are expected in the second quarter of 2025.

Sales and Marketing Organization

Aurinia employs an experienced sales and marketing team dedicated to the commercialization of LUPKYNIS, supported by professionals in commercial operations, commercial supply chain, patient services, and market access functions.

Regulatory Exclusivity

The company has received New Chemical Entity (‘NCE’) exclusivity for LUPKYNIS in the U.S., which provides for exclusivity until January 22, 2026. In the U.S., NCEs approved by the FDA are eligible for market exclusivity under the U.S. Federal Food, Drug, and Cosmetic Act (the ‘FDCA’), which can prevent the approval of generic versions of the NCE for 5 to 7.5 years from the date of the initial approval of the NCE. Specifically, the FDCA provides a 5-year period of marketing exclusivity within the U.S. to the applicant that gains approval of a new drug application (‘NDA’) for an NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the first 4 years of the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application (‘ANDA’) or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all of the data required for approval.

The company also has NCE-equivalent exclusivity for voclosporin in certain European countries, which provides exclusivity for 10 years in Europe post-approval. Additionally, the company has exclusivity for 8 years in Japan post-approval.

Intellectual Property

The company owns granted patents, including U.S. patents, covering LUPKYNIS for composition of matter and methods of use. U.S. Patent Nos. 7,332,472, 10,286,036, and 11,622,991 are listed in the U.S. FDA Orange Book.

The U.S. Patent No. 7,332,472: Patent protection for patents related to the composition of matter of voclosporin is expected to be extended in the U.S. and certain other major markets, including many European markets, until October 2027 under the Hatch-Waxman Act in the U.S., the Supplementary Protection Certificate program in the E.U., and comparable patent extension laws in other countries. In the U.S., the company has applied for a patent term extension for the U.S. Patent No. 7,332,472 and is awaiting confirmation from the USPTO. As the patent term extension was not granted prior to the expiry of the patent term for its composition of matter patent for voclosporin, the company applied for, and has received, an interim patent term extension until October 17, 2025. If the patent term extension is not granted prior to the expiration of the interim patent term extension that was granted, the company intends to file future interim patent term extensions to the extent permitted until the USPTO completes its review of the patent term extension application.

The U.S. Patent No. 10,286,036: In May 2019, the company was granted U.S. Patent No. 10,286,036 with a term extending to December 2037. The patent claims are directed at the LUPKYNIS dosing protocol for LN used in its clinical trials. The company has also filed for protection of this subject matter under the Patent Cooperation Treaty (‘PCT’) and is applying for similar protection in certain member countries thereof. Patents issuing from this PCT application have terms extending to May 2038, and such patents have been issued in Australia, Europe, Hong Kong, Israel, Japan, Korea, Mexico, Malaysia, Russia, and Singapore. Several third parties have filed oppositions against a granted European patent relating to the LUPKYNIS dosing protocol, which the company is vigorously defending. The company has also applied for a patent term extension for the issued Japanese counterpart patent and is awaiting confirmation from the Japan Patent Office (‘JPO’).

The U.S. Patent No. 11,622,991: In April 2023, the company was granted the U.S. Patent No. 11,622,991 with a term extending to December 2037. Importantly, the patent claims reflect the unique and proprietary dosing regimen of LUPKYNIS that is consistent with the FDA-approved product label. This patent specifies the method of treating patients with LN by administering LUPKYNIS in combination with MMF and corticosteroids and using eGFR to pharmacodynamically dose the product. Patents claiming this subject matter have been issued in Japan and Israel, with terms extending to May 2038, and are pending in various other jurisdictions. The company has also applied for a patent term extension for the issued Japanese counterpart patent and is awaiting confirmation from the JPO.

On February 25, 2025, the company received a paragraph IV notice of certification (the ‘Notice Letter’) related to a submission of an ANDA to the FDA seeking authorization to manufacture, use, or sell a generic version of LUPKYNIS in the U.S., prior to the expiry of U.S. Patent Nos. 10,286,036 and 11,622,991 (the ‘2037 Patents’), which are listed in the FDA's Orange Book. The Notice Letter alleges that the 2037 Patents are invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use, or sale of the generic product described in the ANDA.

The company intends to vigorously defend LUPKYNIS and its intellectual property rights protecting LUPKYNIS. In accordance with the Hatch-Waxman Act, because LUPKYNIS is an NCE, should the company file a patent infringement lawsuit within 45 days of receipt of the Notice Letter, the FDA cannot approve any ANDA any earlier than 7.5 years from the approval of the LUPKYNIS NDA unless a District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable, and/or not infringed.

Competition

As a potential treatment for autoimmune disease, AUR200 is subject to competition from both FDA-approved and investigational products. Competing products include, but are not limited to, other dual BAFF/APRIL inhibitors (e.g., povetacicept, atacicept, and telitacicept).

LUPKYNIS’s competition as a treatment in LN patients includes BENLYSTA.

Manufacturing and Supply Chain

The company relies on third-party manufacturers to supply commercial inventory for LUPKYNIS and semi-finished products and expects to continue to do so to meet its development and commercial needs. In all of the company’s manufacturing agreements and commercial supply agreements, it requires that contract manufacturers produce drug substance and drug products in accordance with cGMP and all other applicable laws and regulations.

Manufacturing of Drug Substance

In December 2020, the company entered into a manufacturing services agreement with Lonza for the construction of a dedicated manufacturing facility for voclosporin (the ‘Monoplant’). The construction of the Monoplant began in January 2021 and manufacturing of voclosporin began in late June 2023. The Monoplant is equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacturing of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.

Encapsulation

Catalent Pharma Solutions (‘Catalent’) is currently the sole supplier for the preparation of the company’s voclosporin capsules.

Government Regulation

Any products manufactured or distributed by the company pursuant to FDA approvals are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse experiences with the drug. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic inspections by the FDA and certain state agencies for compliance with the FDA's current Good Manufacturing Practices (‘cGMPs’), which impose certain procedural and documentation requirements on the company and its third-party manufacturers.

The company is subject to a variety of financial disclosure and securities trading regulations as a public company in the U.S., including laws relating to the oversight activities of the U.S. Securities and Exchange Commission (the ‘SEC’) and the regulations of the Nasdaq Global Market, on which the company’s common shares are traded.

History

Aurinia Pharmaceuticals Inc. was founded in 1993. The company was incorporated in 1993.

Aurinia Pharmaceuticals Questions and Answers

Which sectors generate sales and which are the top 3 markets?

Revenue distribution by industry: Biopharmaceuticals: 100% Top 3 markets: USA: approximately 70% Europe: approximately 20% Canada: approximately 10% Aurinia Pharmaceuticals Inc. generates its revenues mainly from the biopharmaceutical industry, with a strong focus on the development and commerci...

At which locations are the company’s products manufactured?

Production Sites: Information not specifically available (2026) Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for the treatment of rare and serious diseases. The company itself does not operate its own production facili...

What strategy does Aurinia Pharmaceuticals pursue for future growth?

Focus on Product Diversification and Market Expansion Aurinia Pharmaceuticals Inc. is pursuing a strategy aimed at product diversification and market expansion. The company plans to expand its product pipeline through the development of new therapies, particularly in the field of autoimmune diseases...

Which raw materials are imported and from which countries?

Main raw materials: Mycophenolate mofetil, Hydroxychloroquine Countries of origin: USA, India, China Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for the treatment of autoimmune diseases. The main raw materials needed...

How strong is the company’s competitive advantage?

Market share: Estimated 10% in the field of lupus nephritis treatment (2026) Patent portfolio: Several patents secured until 2030 Research and Development (R&D): Invested 20% of revenue in R&D (2025) Aurinia Pharmaceuticals Inc. has a significant competitive advantage in the treatment of lup...

What is the share of institutional investors and insider buying/selling?

Institutional Investor Share: 45% (estimated for 2026) Insider Buys/Sells: No significant transactions in the last quarter (2026) The institutional investor share in Aurinia Pharmaceuticals Inc. is approximately 45%, indicating a solid interest from large investment funds and institutional investors...

What percentage market share does Aurinia Pharmaceuticals have?

Market share of Aurinia Pharmaceuticals Inc.: Estimated around 5% (2026) Top competitors and their market shares: GlaxoSmithKline plc: around 15% Roche Holding AG: around 12% Bristol-Myers Squibb Company: around 10% AstraZeneca plc: around 8% Novartis AG: around 7% Pfizer Inc.: around 6% Aurinia Ph...

Is Aurinia Pharmaceuticals stock currently a good investment?

Revenue Growth: 20% (2025) Research and Development Expenses: 30% of revenue (2025) Market Share in Lupus Nephritis Treatment: 25% (2025) Aurinia Pharmaceuticals Inc. recorded a revenue growth of 20% in 2025, attributed to the successful marketing of their main product for treating Lupus Nephritis....

Does Aurinia Pharmaceuticals pay a dividend – and how reliable is the payout?

Dividend: None (as of 2026) Aurinia Pharmaceuticals Inc. currently does not pay a dividend. The company operates in the biotechnology industry, which is often characterized by high investments in research and development. Companies in this industry tend to reinvest profits into developing new produc...

New support ticket

Aurinia Pharmaceuticals Stock Value

Aurinia Pharmaceuticals Company Info

Analyst Price Target

Top growth stocks in the health care sector (5Y.)

What does Aurinia Pharmaceuticals do?

Aurinia Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal